Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Liraglutide
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Approved FDF
Sponsor : Biocon
Deal Size : Undisclosed
Deal Type : Agreement
Biocon Signs Deal for Generic Saxenda® Commercialization in Mexico
Details : Under the agreement, Biocon will obtain regulatory approval and manufacture Saxenda (liraglutide) for chronic weight management, while Medix will commercialize it in Mexico.
Product Name : Saxenda-Generic
Product Type : Peptide
Upfront Cash : Undisclosed
May 13, 2024
Lead Product(s) : Liraglutide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Approved FDF
Sponsor : Biocon
Deal Size : Undisclosed
Deal Type : Agreement